163 related articles for article (PubMed ID: 7838524)
1. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
2. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
Kamikura DM; Naujokas MA; Park M
Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
[TBL] [Abstract][Full Text] [Related]
3. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
Besser D; Bardelli A; Didichenko S; Thelen M; Comoglio PM; Ponzetto C; Nagamine Y
Oncogene; 1997 Feb; 14(6):705-11. PubMed ID: 9038378
[TBL] [Abstract][Full Text] [Related]
5. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein.
Fixman ED; Fournier TM; Kamikura DM; Naujokas MA; Park M
J Biol Chem; 1996 May; 271(22):13116-22. PubMed ID: 8662733
[TBL] [Abstract][Full Text] [Related]
6. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
7. Activation of the JNK pathway is essential for transformation by the Met oncogene.
Rodrigues GA; Park M; Schlessinger J
EMBO J; 1997 May; 16(10):2634-45. PubMed ID: 9184210
[TBL] [Abstract][Full Text] [Related]
8. The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor.
Komada M; Kitamura N
Oncogene; 1993 Sep; 8(9):2381-90. PubMed ID: 7689722
[TBL] [Abstract][Full Text] [Related]
9. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
10. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis.
Royal I; Fournier TM; Park M
J Cell Physiol; 1997 Nov; 173(2):196-201. PubMed ID: 9365521
[TBL] [Abstract][Full Text] [Related]
11. Receptor chimeras indicate that the met tyrosine kinase mediates the motility and morphogenic responses of hepatocyte growth/scatter factor.
Zhu H; Naujokas MA; Park M
Cell Growth Differ; 1994 Apr; 5(4):359-66. PubMed ID: 8043510
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
14. Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1.
Fixman ED; Holgado-Madruga M; Nguyen L; Kamikura DM; Fournier TM; Wong AJ; Park M
J Biol Chem; 1997 Aug; 272(32):20167-72. PubMed ID: 9242692
[TBL] [Abstract][Full Text] [Related]
15. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
16. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
17. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
18. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).
Longati P; Bardelli A; Ponzetto C; Naldini L; Comoglio PM
Oncogene; 1994 Jan; 9(1):49-57. PubMed ID: 8302603
[TBL] [Abstract][Full Text] [Related]
19. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
20. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
